ABSTRACT Background: Micronutrients play an important role in immune function. To our knowledge, there have been no comprehensive studies on the role of micronutrient supplementation in children with tuberculosis. Objective: We assessed the effect of micronutrient supplementation in children treated with antituberculosis therapy (ATT). Design: A randomized, double-blind, placebo-controlled trial that used a 2 3 2 factorial design was undertaken at 2 teaching hospitals in Delhi. Children with newly diagnosed intrathoracic tuberculosis were enrolled, and they received ATT together with daily supplementation for 6 mo with either zinc alone, micronutrients without zinc, micronutrients in combination with zinc, or a placebo. Main outcomes were weight gain and an improvement in a chest X-ray (CXR) lesion assessed at 6 mo of treatment. Results: A total of 403 children were enrolled and randomly assigned. A microbiological diagnosis of tuberculosis was confirmed in 179 children (44.4%). The median (95% CI) increase in weight-for-age z score at 6 mo was not significantly different between subjects who received micronutrients [0.75 (0.66, 0.84)] and those who did not receive micronutrients [0.76 (0.67, 0.85)] and between subjects who received zinc [0.76 (0.68, 0.85)] and those who did not receive zinc [0.75 (0.66, 0.83)]. An improvement in CXR was observed in 285 children, but there was no difference between those receiving zinc and no zinc or between those receiving micronutrients and no micronutrients after 6 mo of ATT. However, children who received micronutrients had a faster gain in height over 6 mo than did those who did not (height-for-age z score D = 0.08; P = 0.014). Conclusions: Micronutrient supplementation did not modify the weight gain or clearance of lesions on CXR in children with intrathoracic tuberculosis. However, micronutrient supplementation during treatment may improve height gain in children with intrathoracic tuberculosis. This trial was registered at clinicaltrials.gov as NCT00801606.
INTRODUCTION
Micronutrient deficiencies impair the immune system with subsequent higher risk of infections as well as poorer prognosis (1, 2) . Micronutrient deficiencies are widespread in the developing world and are thought to contribute to the high burden and poor outcomes of many infectious diseases including tuberculosis (3) (4) (5) (6) . Globally, 1.5 million new cases and 130,000 deaths as a result of tuberculosis are reported annually (7) in children, which make tuberculosis an important cause of childhood morbidity and mortality.
The nutritional rehabilitation of tuberculosis patients may enhance the proliferation of T-lymphocyte subpopulations in response to specific antigens and influence key cytokines involved in the formation of organized granulomas and macrophage activation (8) . Micronutrients, especially zinc, are crucial components of both intracellular and intercellular signaling systems of most immunocompetent cells with subsets of T lymphocytes and monocytes being most affected in zinc deficiency. In addition, the macrophage, which is a pivotal cell in the host defense against tuberculosis, is adversely affected by zinc deficiency (9) .
A better understanding of the relations between isolated or combined micronutrient deficiencies and tuberculosis can lead to interventions to reduce the burden and improve outcomes. Although many studies have documented a high prevalence of vitamin D deficiency in patients with tuberculosis (10) (11) (12) (13) (14) , there have been few studies with contrary results (15) , and vitamin D supplementation trials have not shown consistent improvements in outcomes (16) (17) (18) (19) (20) . Vitamin A and zinc supplementation showed improved sputum conversion in adult Indonesian sputum positive tuberculosis patients (21) . Although multimicronutrient supplements with zinc have shown improved outcomes, supplements without zinc did not (22) .
Although micronutrient deficiencies may influence the immune system in both adults and children, the pertinent issues of growth and development are unique to the pediatric population. Because of the high growth rate and developing immune system, micronutrient deficiencies are likely to be more widespread in children and as a consequence supplementation is important. Little is known about the effect of micronutrient supplementation on childhood tuberculosis outcomes; a study in children with tuberculosis from Tanzania reported no effect on weight gain after 8 wk of multivitamin supplementation (23) .
We carried out a randomized, double-blind, placebo-controlled trial in children with newly diagnosed intrathoracic tuberculosis in a high tuberculosis burden setting. The aim of the study was to assess the effect of micronutrient supplementation on treatment outcomes in children with intrathoracic tuberculosis. Primary outcomes were the change in weight-for-age z score (WAZ) 5 at 6 mo and resolution of pulmonary lesions as assessed by using a chest X-ray (CXR) at 6 mo. Secondary outcomes were 1) heightfor-age z score (HAZ), midupper arm circumference, triceps skinfold thickness, and BMI z score at 2 and 6 mo; 2) a resolution of symptoms as reported by parents at 2 mo; 3) the proportion of children requiring extension of intensive phase of therapy at 2 mo; and 4) the improvement in the CXR at 2 mo.
SUBJECTS AND METHODS
This randomized, double-blind, placebo-controlled trial, with the use of a 2 3 2 factorial design, was carried out from January 2008 to June 2012 at the All India Institute of Medical Sciences and Kalawati Saran Children Hospital associated with Lady Hardinge Medical College in Delhi, India. The study protocol was approved by the respective institutional ethics committees. This trial was registered at clinicaltrials.gov as NCT00801606.
Patient eligibility and assessment
Children from 6 mo to 15 y of age who presented with any of the following symptoms were considered tuberculosis suspects and screened for tuberculosis (24): 1) cough .2 wk with no improvement after a 7-10-d course of amoxicillin; 2) fever .2 wk with no improvement during a 7-10-d course of amoxicillin; 3) recent unexplained weight loss or failure to thrive; 4) unusual or unexplained fatigue (reduced playfulness) or lethargy; or 5) subtle clinical symptoms and history of close contact with adult patient with tuberculosis. All tuberculosis suspects underwent a CXR (lateral and posterior-anterior) and a tuberculin skin test (TST). If the CXR, as read by the site investigator, was consistent with intrathoracic tuberculosis (ie, hilar or mediastinal adenopathy, consolidation, cavity, miliary shadows, or pleural effusion), the child was classified as having probable intrathoracic tuberculosis. This diagnostic algorithm was similar to what is recommended by the Revised National Tuberculosis Control Program for childhood tuberculosis (25) .
Children with newly diagnosed probable intrathoracic tuberculosis, with or without an extrapulmonary lesion, were considered for enrollment. Children were excluded if they had any of the following: 1) bilateral pedal edema; 2) known HIV infection; 3) history of antituberculosis treatment or isoniazid prophylaxis .4 wk; 4) signs of an upper-airway obstruction; 5) oxygen saturation ,92%; 6) signs of renal, hepatic, or cardiovascular disease; 7) inability to attend follow-up session for reading of the TST; 8) documented intake of zinc continuously .2 wk in the 4 wk preceding enrollment; 9) central nervous system, osteoarticular, pericardial, or renal tuberculosis; 10) history of contact with a documented case of drug-resistant tuberculosis; or 11) were nonresidents of Delhi. Children were not routinely tested for HIV infection. However, stored serum samples of children enrolled in the randomized controlled trial were anonymously tested for HIV, and the prevalence was shown to be 1%.
Written informed consent was obtained from guardians of children. For children .7 y of age, written assent was also taken.
Antituberculosis therapy regimen
All patients received the drug regimen as per the recommendation of the Revised National Tuberculosis Control Program of India; this regimen had a 2-mo intensive phase that used 3 or 4 drugs (isoniazid, rifampicin, pyrazinamide and ethambutol) followed by 4 mo of isoniazid and rifampicin (25, 26) . Category 1 treatment was the use of 4 drugs (isoniazid, rifampicin, pyrazinamide, and ethambutol) in the intensive phase followed by 4 mo of 2 drugs (isoniazid and rifampicin), whereas category 3 treatment was the use of 3 drugs (isoniazid, rifampicin, and pyrazinamide) in the intensive phase followed by 4 mo of maintenance phase of 2 drugs. Antituberculosis therapy (ATT) was administered in daily doses on the basis of weight (ie, 5-7 mg isoniazid/kg, 10-13 mg rifampicin/kg, 35-40 mg pyrazinamide/kg, and 20-25 mg ethambutol/kg.
Random assignment, allocation concealment, and intervention
All patients received the standard of care including ATT. In addition, for 6 mo, participants received a daily dose of 5 mL syrup preparation that contained 1 of 4 regimens as follows: 1) zinc (20 mg elemental zinc) only; 2) micronutrients (vitamin A, thiamine, riboflavin, vitamins B-6 and B-12, folic acid, niacin, vitamins C, E, and D, selenium, and copper) without zinc; 3) micronutrients in combination with zinc (vitamin A, thiamine, riboflavin, vitamin B-6 and B-12, folic acid, niacin, vitamins C, E, and D, selenium, copper, and 20 mg elemental zinc); or 4) placebo. Micronutrient preparations and the placebo were purchased from Messers Inda Medica.
Doses of the micronutrients other than zinc were based on age (ie, 6 mo to 3 y, 4-6 y, 7-9 y, and 10-15 y) ( Table 1) . Doses given correspond to 1-2 times the RDA according to age (27) , except for zinc, for which 20 mg was given to all children because of the high requirements during catch-up growth.
Children were randomly assigned to 1 of 4 interventions. A scientist, who was not involved in the data collection and analysis, generated random-allocation sequences in permuted blocks of variable sizes separately for the 2 sites. Separate sequences were generated for the age groups 6 mo to 3 y, 4-6 y, 7-9 y, and 10-15 y. Bottles that contained the micronutrient supplements were serially numbered for each stratum for the 2 sites. The 4 study syrup preparations had a similar packaging, appearance, and smell. The patient, physician, and laboratory personnel were blinded to the intervention. We maintained the masking during the data 5 Abbreviations used: AFB, acid fast bacillus; ATT, antituberculosis therapy; CXR, chest X-ray; DSMB, data safety and monitoring board; DST, drug-sensitivity testing; HAZ, height-for-age z score; MGIT, mycobacterial growth indicator tube; MTB, Mycobacterium tuberculosis; MUAC, midupper arm circumference; NCHS, National Center for Health Statistics; TST, tuberculin skin test; WAZ, weight-for-age z score.
analysis by coding the treatment allocation with 4 letters. All patients were provided with ATT and the study supplement in sufficient quantity until the next visit with 5 additional doses.
Assessment of adherence
Adherence to medications and supplementation was assessed by providing a diary to the guardian who was asked to maintain a daily record that indicated the administration of the study intervention and ATT. In addition, adherence was assessed at each visit by counting remaining pills (ATT) and measuring the volume of the remaining study syrup. Patients' guardians were reminded of the visit to the clinic 1 d in advance by telephone. If a patient did not attend the clinic on the assigned date, the parent or guardian was contacted by telephone. If telephone contact was not feasible, a fieldworker visited the child's home.
Clinical and laboratory evaluation
All patients enrolled in the study were assessed for clinical symptoms, history of tuberculosis contact, history of Bacillus Calmette-Gue´rin vaccination, demographic information, detailed anthropometric measurements, and physical examination. Patients were followed every 2 wk until 2 mo of treatment and, thereafter, every 4 wk until they completed the assigned ATT. On each follow-up visit, a detailed clinical history and examination including anthropometric measurements were recorded. Dietary history was recorded by the 24-h dietary recall method. The nutritive value of the diet was calculated by using Dietsoft software (Invincible IDeAS).
Anthropometric measures
Child's weight was measured with minimal clothing to the nearest 0.1 kg by using an electronic scale. Children ,2 y old were weighed by using an infant weighing scale, and their lengths were measured by using an infantometer to the nearest 0.1 cm. In children able to stand and .2 y of age, height was measured by using a stadiometer to the nearest 0.1 cm. The midupper arm circumference was measured to the nearest 0.1 mm by using nonstretchable tape. Triceps skinfold thickness was measured by using a Harpenden skinfold-thickness caliper (Baty British Indicators) to the nearest 0.1 mm. All the measurements were taken on each visit by the same observer as far as possible to avoid interobserver variation. Periodic quality-control exercises were carried out at both centers by senior study investigators. The WAZ, HAZ, and weight-for-height z score were calculated by using the nutritional anthropometry module of Epi Info version 5 software (CDC) on the basis of the National Center for Health Statistics-WHO reference curves 2000 (28) .
Laboratory workup
Gastric lavage and sputum induction on 2 consecutive days were performed on an ambulatory basis [baseline and at 2 mo if the baseline sample was positive for acid fast bacillus (AFB) by smear or mycobacterial growth indicator tube (MGIT) culture and at 6 mo if the AFB smear or MGIT culture was positive at 2 mo). Samples were processed for smear examination and culture for Mycobacterium tuberculosis (MTB) as reported earlier (29) . For the purpose of study, the drug-sensitivity testing (DST) was done on isolates that were stored, and therefore, the same could be done in only a proportion of children. However, in specific scenarios of nonresponse or worsening, DST was requested for and obtained earlier.
A QuantiFERON Gold in-Tube test (Cellestis) was performed at baseline and 2 and 6 mo as per the manufacturer's guidelines (30) .
Serum zinc and copper (baseline and 2 and 6 mo) were determined by using a flame furnace atomic absorption spectrophotometer (GBC Avanta) by using standard techniques and with Seronorm Trace Elements Serum (Sero AS). Limits of detection were 10-160 mg/dL for serum zinc and 40-320 mg/dL for copper. For outliers above limits of detection, the sample was further diluted and reassayed, and the concentration was calculated accordingly. For quality control, pooled serum with a known value was used. Interassay variability remained ,10%. Serum zinc concentrations ,65 mg/dL were considered low (31) .
CXR was performed at baseline and 2 and 6 mo of enrollment. All CXRs were read initially by site investigators who undertook patient enrollment into the study. CXRs shown to be of poor quality were repeated. The reading of CXRs for the study purpose was done subsequently by 2 pediatricians (VS, SKK, or RL) who were blinded for the clinical diagnosis of patient, and a standardized format was used for reporting. If findings of the 2 pediatricians differed, the third person was asked to review the CXR and final findings that matched for 2 of the pediatricians were recorded for the purpose of analysis. CXRs taken at 2 and 6 mo were classified as follows: significant improvement (more than twothird clearance from baseline), some improvement (improvement but less than two-third clearance from baseline), no improvement (no change in lesion size), and worsening (increase in the lesion size from baseline) (32) . A TST was performed by using 5 tuberculin units purified protein derivative (Span Diagnostics), which was administered intradermally by a trained study nurse on the flexor aspect of the left forearm. Induration (transverse diameter) was measured between 48-72 h after the test was applied. Any induration $10 mm was considered as positive.
Wherever indicated, additional laboratory investigations including fine-needle aspiration cytology, biopsy of lymph node, 
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and a pleural fluid examination were performed, and culture on the MGIT was done.
Trial deviates
A participant was registered as a trial deviate for the following reasons: 1) if the duration of interruption of ATT was .2 wk in the intensive phase and .4 wk in the maintenance phase; 2) the patient received a zinc preparation .2 wk during enrollment in the study; or 3) the patient had an HIV infection diagnosed after the start of study.
Change of therapy
ATT was changed to category 2 in the case of a nonresponse either clinical or radiological. Category 2 ATT includes 2 mo of streptomycin, isoniazid, rifampicin, pyrazinamide, and ethambutol followed by 1 mo of isoniazid, rifampicin, pyrazinamide, and ethambutol and 5 mo of isoniazid, rifampicin, and ethambutol (26) . Any child who did not improve with category 2, and for whom an alternative diagnosis had been ruled out, was started on second-line ATT, which included an injection of kanamycin, ofloxacin, and ethionamide and an additional drug (cycloserine or coamoxyclav). Any child who completed the total duration of therapy, irrespective of the regimen administered, was considered as having completed therapy.
Quality assurance and monitoring of adverse events
Before study initiation, study procedures were standardized, and standardized operating procedure manuals were prepared. All study staff were trained and monitored periodically at both sites. A data safety and monitoring board (DSMB) was constituted, and DSMB members met before the study initiation and every 3 mo after the study start. All adverse events were communicated to the DSMB. Good Clinical Practice guidelines for the monitoring of clinical trials were adhered to.
Sample-size calculation
There are limited data on the radiological response to ATT in children with pulmonary tuberculosis. On the basis of clinical experience from the 2 participating centers, we assumed that, after 6 mo of ATT, 60% of children in the placebo arm would have a significant resolution of CXR tuberculosis lesion. We anticipated that, in the intervention arm, 80% of children would have a significant resolution of tuberculosis lesion on the CXR, which would be a clinically significant effect. With a power of 80% and a error of 0.05, a sample size of 91 children/group was required to detect an increase in the proportion with resolution $80% in micronutrient-or zinc-supplemented children. With the allowance for 10% attrition, we required a sample size of 100 children/group (ie, a total trial size of 400 children). This sample size would enable us to detect a 10% change in WAZs between groups.
Data management and statistical analysis
Site supervisors checked all completed case-report forms before they were sent for interactive double data entry by using MS Access software (version 2007; Microsoft Corp) with built-in logic, consistency, and range checks. Data were analyzed according to the intention-to-treat principle, which, because of few missing data at follow-up, resulted in available case analyses. All analyses were done with Stata 11.0 software (StataCorp).
Treatment completion, change of therapy, lost to follow-up, deaths, and withdrawals by intervention arm were assessed by using either chi-square tests or Fisher's exact tests when appropriate. All children who completed their ATT, irrespective of the regimen they were assigned to, were considered under the treatment-completion category.
Main-effect analyses were based on a 2 3 2 factorial design (33), and because of repeated measures, we used linear mixedeffects models for continuous outcomes (WAZ, HAZ, triceps skinfold thickness, midupper arm circumference, and BMI z score) with study identification numbers included as random effects. Primarily, effects of the interventions (micronutrients or zinc) were evaluated by using unadjusted analyses with the follow-up visit variable as a fixed effect. Second, adjusted models were obtained by additionally including a number of fixed effects (age, sex, mother's education, father's education, diagnosis, and energy and zinc intakes) and random effects (study site). We assessed interactions between zinc and micronutrient groups in the adjusted analysis. Results from adjusted models were only shown when estimates and interpretations of results changed.
In addition, the CXR variable at follow-up was considered to be recorded on an ordinal scale (worsening, no change, some improvement, and significant clearance). Thus, with respect to zinc and micronutrients, the intervention data analysis was based on Wilcoxon's rank-sum test at 2 and 6 mo of follow-up, respectively.
Serum zinc and copper were measured at baseline and follow-up with changes over time as well as differences between micronutrients compared with no micronutrients and zinc compared with no zinc (2 3 2 factorial design) assessed by using linear mixed-effects models with identification numbers as random effects. In unadjusted analyses, the intervention (micronutrients or zinc) and follow-up visit were added as fixed effects. Adjusted analyses also included the following fixed-effects variables: age, sex, mother's education, father's education, diagnosis, and energy and zinc intakes as well as random effects for study sites.
RESULTS
Of 1572 children screened, 52.2% of subjects (820 children) were diagnosed as having probable intrathoracic tuberculosis. A total of 417 children were excluded (Figure 1) , and 49.1% of subjects (403 of 820 children) were enrolled in the study and randomly assigned to 1 of 4 interventions (Figure 1 ). Data on any 1 of 2 primary outcomes were available at 2 mo for 97.5% (393 children) and at 6 mo for 94.5% (381 children) of 403 subjects.
For most demographic and clinical profiles, intervention arms were comparable at baseline; however, some differences were identified with regards to sex distribution, parental educational level, diagnosis, and energy and zinc intakes before enrollment ( Table 2) . Nearly one-half of children (54.3%) had serum zinc concentrations ,65 mg/dL. The median (IQR) monocyte:lymphocyte ratio at baseline was 0.054 (0-0.29) and was significantly different in 3 types of disease categories as classified by the CXR (P = 0.003), with the lowest in progressive disease.
DST was carried out in 63.9% of children (94 of 147 subjects) at baseline. The mean (6SD) time to positivity for MGIT culture
Adherence to the study supplement was high (96.3%) in all study groups as was adherence to ATT (95%) ( Table 3) .
Sixty children (14.9%) required an extension of the 4-drug intensive phase of treatment because of a nonresolution of symptoms or persistence of AFB in the smear from gastric lavage or induced sputum. The treatment regimen had to be changed to category 2 or second-line ATT in 24 children (5.9%). The distribution of these patients between the 4 arms of the study was not significantly different. Drug sensitivity could be done in only 94 of 147 culture-positive children (63.9%). Five children (5.3%) had multidrug-resistant tuberculosis; 4 children had received a category 2 treatment, whereas one child was started directly on second-line treatment. Of 152 children who tested positive for AFB in the smear or MTB in MGIT culture at baseline, AFB was positive in the smear from gastric lavage and/or induced sputum at the end of 2 mo of ATT in 13 children (8.5%), whereas MTB FIGURE 1. Flow of study. 1 A participant was registered as a trial deviate for the following reasons: 1) if the duration of interruption of ATT was .2 wk in the intensive phase and .4 wk in the maintenance phase; 2) if the participant was receiving a zinc preparation .2 wk during enrollment in the study; or 3) if the participant had HIV infection diagnosed after the start of study. ATT, antituberculosis therapy. culture was positive in 41 children (26.9%). There was no difference in the distribution of children who did not undergo smear and culture conversion at the end of 2 mo of therapy between the 4 groups.
Primary outcomes
Change in WAZ At 6 mo, the median weight gain was 4.0 kg (95% CI: 3.4, 4.7 kg), and the WAZ was 0.75 (95% CI: 0.69, 0.82). The change in the WAZ was assessed at 2 and 6 mo ( Table 4 ). There was no interaction between micronutrients and zinc groups at both follow-up time points (P-interaction . 0.48). The median increase in WAZ at 6 mo was not significantly different between subjects receiving micronutrients (0.75; 95% CI: 0.66, 0.84) compared with no micronutrients (0.76; 95% CI: 0.67, 0.85) and zinc (0.76; 95% CI: 0.68, 0.85) compared with no zinc (0.75; 95% CI: 0.66, 0.83). Additional adjustment did not change results.
Improvement in CXR
A total of 285 children (74.8%) showed significant improvement on the CXR at 6 mo of treatment. There was no difference in CXR changes between subjects receiving zinc compared with no zinc or micronutrients compared with no micronutrients at 6 mo of ATT (Table 4 ).The agreement between 2 readers was 63.3% (k = 0.28) for CXRs done at 2 mo and 65% (k = 0.29) for CXRs done at 6 mo. 
Secondary outcomes
Micronutrient supplementation increased the HAZ at 6 mo (difference: 0.08; 95% CI: 0.02, 0.14); full adjustment did not change the effect estimate (difference: 0.08; 95% CI: 20.02, 0.18). There were no effects of micronutrients supplementation on other anthropometric outcome, and no effects of zinc supplementation were observed on any of the anthropometric outcomes ( Table 5) . Additional adjustment did not change estimates. There were no interactions between micronutrient and zinc interventions.
At the end of the intensive phase of ATT (2 mo), 80% of children showed an improvement in cough, 94.6% of children showed an improvement in fever, 95.4% of children showed an improvement in appetite, and 94.2% of children, showed an improvement in lymphadenopathy.
Except for subjects who were not receiving zinc, serum zinc increased over 6 mo of treatment ( Table 6 ). Serum copper decreased over 6 mo in all treatment arms. Dietary intakes of energy and zinc were comparable in the 4 groups at 2 and 6 mo (data not shown). 2 All children who completed their antituberculosis therapy, irrespective of the regimen they were assigned to, are considered under treatment completion.
3 ATT, antituberculosis therapy.
TABLE 4
Effect of micronutrient supplementation on weight-for-age z score and resolution of lesions on a chest X-ray at 2 and 6 mo in children with intrathoracic tuberculosis randomly allocated to micronutrient or placebo and zinc or placebo supplementation 2 All values are bs; 95% CIs in parentheses. Values were determined by using an unadjusted linear mixed-effects model with follow-up time as a fixed effect and the participant as a random effect. Data were analyzed as intention to treat on the basis of the available case analysis. The interaction between micronutrient and zinc supplementation was tested in an unadjusted model (P-interaction = 0.68) and a model with additional fixed (age, sex, maternal and paternal educational level, baseline diagnosis, and energy and zinc intakes) and random (study site) effects (P-interaction = 0.48).
3 Differences were tested by using the Wilcoxon's rank-sum test at 2 and 6 mo, respectively.
In 313 children, 690 episodes of adverse events were documented. Adverse events included upper respiratory tract infection, megaloblastic anemia, hepatitis, and vomiting and were unrelated to study interventions. There were 5 deaths (2 deaths each in the micronutrient-zinc and micronutrients groups, one death in the zinc group, and no deaths in the placebo group). None of the deaths were related to study interventions. The final diagnosis in these 5 cases were miliary tuberculosis with grade 3 protein-energy malnutrition with secondary infection, pulmonary tuberculosis with secondary sepsis, septic shock with intestinal perforation, pulmonary tuberculosis with septic shock, and pulmonary tuberculosis with super infection with rickets and respiratory failure.
DISCUSSION
We did not observe any effect of micronutrient or zinc supplementation on weight gain or resolution in CXR lesions in children with newly diagnosed intrathoracic tuberculosis treated with antituberculosis drugs. However, children who were receiving micronutrients supplements had greater linear growth. We did not observe any differences in the proportion of children who showed sputum conversion or treatment failures with regard to the intervention.
In the past decade, there has been considerable interest in studying the effect of micronutrient supplementation on outcomes of pulmonary tuberculosis; most of these studies have been carried out in adult patients. To our knowledge, there has only been one recently published randomized controlled trial that compared multivitamin supplementation (vitamins B complex, C, and E) for 8 wk with placebo in childhood tuberculosis (23) . No differences in the clearance of CXR, weight gain, or mortality rates were observed in 255 children who participated in the trial (23) . The study was limited to children ,5 y of age, and only vitamins were supplemented for a shorter period of 8 wk (23) . A small
TABLE 5
Height-for-age z score, triceps skinfold thickness, arm circumference, and BMI-for-age z score results at 0, 2, and 6 mo in 403 children infected with tuberculosis randomly allocated to micronutrient or placebo and zinc or placebo supplementation (34) . Effects of micronutrients used in various combinations have been reported in adult tuberculosis patients by using different outcome measures. Initial reports from such studies were encouraging; however, the more-recent ones have not been able to support the beneficial role of micronutrient supplementation in the tuberculosis outcome (18) (19) (20) . Although vitamin D deficiency is common in patients with tuberculosis, the effect of supplementation on plasma concentrations has been inconsistent. Vitamin D supplements may have a beneficial effect on early sputum conversion, but larger trials are needed to confirm this effect (16, 35) .
Effects on growth
We did not observe any effects of micronutrients or zinc supplementation on weight gain in children who were suffering from intrathoracic tuberculosis. In adults, supplementation with micronutrients and zinc increased weight gain in Tanzanian tuberculosis patients (22) . A later, larger study in the same population also showed increased weight gain but only in HIV-negative tuberculosis patients (36) . In contrast, there were no effects of vitamin A and zinc supplementation in adult tuberculosis patients neither in Indonesia (21, 37) nor South Africa (38) . A recent guideline on nutritional supplementation did not recommend any additional micronutrient supplementation for patients with active tuberculosis (39) .
Micronutrient supplements do not provide energy, and thus, an effect on weight is only conceivable if supplements increase appetite and, hence, energy intake, if supplements increase the synthesis of lean rather than fat mass, or if supplements prevent or lead to a faster recovery from diseases. Effects of supplementation with zinc and other micronutrients are likely to differ between populations, because the background intake and status are likely to be different, and effects are only likely if deficiencies are widespread (40) .
In contrast, we showed that micronutrient but not zinc supplementation was associated with a higher gain in height. However, height gain was not a predefined outcome, and this result could have been an incidental finding. Nevertheless, in the trial in children with tuberculosis in Tanzania, an effect of multivitamins on height was also seen but only in a subgroup of HIV-positive children (23) . Meta-analyses of studies in healthy children in lowincome countries showed that micronutrient supplementation improved linear growth (41) , and zinc supplementation improved both linear and ponderal growths (42). We did not see any effect of zinc on linear growth, which could have been due to the lack of other growth nutrients. A systematic review reported no significant improvement in death rates and smear positivity at 1 and 2 mo with the use of multiple micronutrient supplements in adult patients (35, 36) .
Effects on resolution of CXR findings
The radiological improvement in our cohort of children was good across all intervention arms. These results were obtained in the setting of a clinical trial, which may have been different from in a routine setting. Specific provisions were made to ensure 1 All values are bs; 95% CIs in parentheses. No-micronutrient group: groups receiving only zinc and placebo. Micronutrient group: group receiving micronutrient supplementation alone 1 group receiving micronutrient and zinc combined. No-zinc group: groups receiving micronutrient alone and placebo. Zinc group: group receiving zinc alone and group receiving micronutrient and zinc combined. Values were determined by using an unadjusted linear mixedeffects model with follow-up time as a fixed effect and the participant as a random effect. Data were analyzed as intention to treat on the basis of the available case analysis. The interaction between micronutrient and zinc supplementation was tested in an unadjusted model and a model with additional fixed (age, sex, maternal and paternal educational level, baseline diagnosis, and energy and zinc intakes) and random (study site) effects. In the fully adjusted model, there was no interaction between micronutrient and zinc for serum zinc (P = 0.21) and serum copper (0.08). In the unadjusted analysis, there was an interaction between micronutrient and zinc for serum zinc (P = 0.02) but not serum copper (P = 0.09).
adherence and follow-ups, which were likely to have positively influenced overall outcomes.
We did not show any influence of zinc or micronutrients supplementation on CXR resolution in our cohort of children. A study in Tanzanian children could not show any improvement in CXR resolution in vitamin-supplemented compared with placebo groups (23) . Studies in adult populations have documented inconsistent effects of micronutrient supplementation on CXR resolution. Karyadi et al (21) documented an earlier resolution of CXR lesions with vitamin A and zinc supplementation in Indonesian patients, but a later study by the same groups refuted this observation (37) . A study on South African patients too could not show any beneficial effect of vitamin A and zinc supplementation on CXR resolution rates (38) .
Effects on sputum conversion rates
We did not find any difference in the sputum conversion across intervention arms of this study. An earlier sputum conversion was shown in adult Indonesian tuberculosis patients who were supplemented with vitamin A and zinc (21) . A later trial, in severely malnourished Indonesian tuberculosis patients, did not confirm that a single or combined supplementation of zinc and vitamin A significantly reduced sputum conversion time or had other significant benefits (37) . A systematic review reported no significant improvement in death rates and smear positivity at 1 and 2 mo with the use of micronutrient supplements in adult patients (43, 44) . Serum zinc was observed to be increasing with supplementation as was expected, but this result did not translate into a greater improvement in anthropometric outcomes in these children. Serum copper showed declining trends with ATT irrespective of supplementation. This result might have been because copper and ceruloplasmin are positive acute-phase reactants (45) .
There have been some attempts to look into the effect of micronutrient supplementation on the cell-mediated immunity against tuberculosis. Kawai et al (46) observed that there was no beneficial effect of vitamins (A, B complex, C, and E) and selenium supplementation on the lymphocyte proliferation in response to mycobacterial proteins. Doses used in the current trial and previously reported trials may have been insufficient for a therapeutic effect; additional studies may consider the use of higher doses of micronutrients.
Strengths of our study included the double-blind, randomized, placebo-controlled, 2 3 2 factorial design with a sufficient sample size and low loss to follow-up. Limitations included that the confirmatory diagnosis was based on clinicoradiologic features and not only on a microbiologic basis; however, we had a microbiologic confirmation in 44.4% of subjects. Analyses of data in subjects with microbiologically confirmed tuberculosis were not significantly different (data not shown). Primary outcomes were weight gain and radiologic clearance; radiologic findings may have been subjective. We tried to minimize the subjectivity; CXRs were read by 2 pediatricians who were unaware of clinical features and outcomes. A standardized format was used to report findings of X-ray films; the agreement between 2 readers was fair. The interobserver variability in readings of CXRs in pediatric patients has been often reported (47, 48) . To counteract this variability, a third pediatrician was asked to read CXRs in cases of disagreement between the first 2 readers, and the majority decision was accepted. No adjustment for multiple comparisons was made because primary outcomes were nonsignificant.
In conclusion, micronutrient supplementation does not modify the outcome of childhood intrathoracic tuberculosis in the form of weight gain or X-ray clearance. However, micronutrient supplementation with or without zinc may improve linear growth in children with intrathoracic tuberculosis. Additional trials that use different formulations and doses may be performed to evaluate the role of micronutrient supplementation in childhood tuberculosis.
